Related Experiment Video
Updated: Apr 12, 2026
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Kidney cancer and 2014: is innovation really over?
Chiara Ciccarese1, Alessandra Modena, Giampaolo Tortora
1Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Piazzale LA Scuro 10, 37124 Verona, Italy.
Abstract:
2014 has been a year of significant innovations on kidney cancer treatments, the most relevant of which will be shown below. In particular, we analyzed the consolidated knowledge regarding the role of surgery in localized and advanced renal cell carcinoma and the targeted therapies already approved for metastatic renal cell carcinoma. Furthermore, we examined the outstanding issues, with particular reference to the choice of the second-line and the role of adjuvant and neoadjuvant treatments. Finally, we outlined the future therapeutic perspectives and those definitely abandoned.
Insights
Innovations in kidney cancer treatment in 2014 focused on surgery for localized and advanced renal cell carcinoma and targeted therapies for metastatic disease. Key issues included second-line treatments and adjuvant/neoadjuvant approaches, with future perspectives also discussed.
Area of Science:
- Oncology
- Urology
Background:
- 2014 saw significant advancements in kidney cancer therapeutics.
- Established knowledge on surgical roles and targeted therapies for renal cell carcinoma was analyzed.
Purpose of the Study:
- To review key innovations in kidney cancer treatment from 2014.
- To analyze the current understanding of surgical and targeted therapy applications.
- To examine unresolved questions and future directions in renal cell carcinoma management.
Main Methods:
- Review of consolidated knowledge on surgical interventions for localized and advanced renal cell carcinoma.
- Analysis of approved targeted therapies for metastatic renal cell carcinoma.
- Examination of second-line treatment choices, adjuvant, and neoadjuvant strategies.
Main Results:
- Consolidated knowledge regarding surgery in localized and advanced renal cell carcinoma.
- Approved targeted therapies for metastatic renal cell carcinoma.
- Outstanding issues including second-line treatment selection and adjuvant/neoadjuvant roles.
Conclusions:
- The year 2014 brought significant progress in kidney cancer treatment modalities.
- A comprehensive overview of surgical roles, targeted therapies, and future perspectives was presented.
- Key challenges and abandoned therapeutic avenues were also highlighted.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:56Treatment Resistent Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
02:18Cancer